JP5379692B2 - 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 - Google Patents
潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 Download PDFInfo
- Publication number
- JP5379692B2 JP5379692B2 JP2009535728A JP2009535728A JP5379692B2 JP 5379692 B2 JP5379692 B2 JP 5379692B2 JP 2009535728 A JP2009535728 A JP 2009535728A JP 2009535728 A JP2009535728 A JP 2009535728A JP 5379692 B2 JP5379692 B2 JP 5379692B2
- Authority
- JP
- Japan
- Prior art keywords
- heteroaryl
- aryl
- compound
- alkyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC*CC(C(c1ccccc1)=C1O)N(CCC[n]2cncc2)C1=O Chemical compound CC*CC(C(c1ccccc1)=C1O)N(CCC[n]2cncc2)C1=O 0.000 description 1
- JMEZETREXPPDRQ-UHFFFAOYSA-N OC(C(N(CCC[n]1cncc1)C1c(cccc2)c2F)=O)=C1c1ccccc1 Chemical compound OC(C(N(CCC[n]1cncc1)C1c(cccc2)c2F)=O)=C1c1ccccc1 JMEZETREXPPDRQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86498606P | 2006-11-09 | 2006-11-09 | |
| US60/864,986 | 2006-11-09 | ||
| PCT/EP2007/062030 WO2008055945A1 (en) | 2006-11-09 | 2007-11-08 | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013154932A Division JP5798157B2 (ja) | 2006-11-09 | 2013-07-25 | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010509284A JP2010509284A (ja) | 2010-03-25 |
| JP2010509284A5 JP2010509284A5 (https=) | 2011-02-17 |
| JP5379692B2 true JP5379692B2 (ja) | 2013-12-25 |
Family
ID=39048871
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535728A Expired - Fee Related JP5379692B2 (ja) | 2006-11-09 | 2007-11-08 | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| JP2013154932A Expired - Fee Related JP5798157B2 (ja) | 2006-11-09 | 2013-07-25 | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013154932A Expired - Fee Related JP5798157B2 (ja) | 2006-11-09 | 2013-07-25 | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8278345B2 (https=) |
| EP (1) | EP2089383B1 (https=) |
| JP (2) | JP5379692B2 (https=) |
| WO (1) | WO2008055945A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010009987A2 (en) | 2008-07-21 | 2010-01-28 | Probiodrug Ag | Diagnostic antibody assay |
| TW201016702A (en) | 2008-09-25 | 2010-05-01 | Shionogi & Co | Novel pyrrolinone derivative and pharmaceutical composition comprising the same |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| WO2011076854A1 (en) | 2009-12-22 | 2011-06-30 | Probiodrug Ag | CLEAVAGE OF β-AMYLOID PRECURSOR PROTEIN |
| WO2011101433A1 (en) | 2010-02-18 | 2011-08-25 | Probiodrug Ag | Methods of diagnosing inflammatory diseases by determining pyroglutamate-modified mcp-1 and screening methods for inhibitors of glutaminyl cyclase |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| JP5952816B2 (ja) | 2010-08-19 | 2016-07-13 | プロビオドルグ エージー | グルタミニルシクラーゼの結晶構造 |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| CA2828433C (en) | 2011-03-16 | 2020-08-04 | Probiodrug Ag | Diagnostic antibody assay |
| SG194770A1 (en) * | 2011-05-27 | 2013-12-30 | Probiodrug Ag | Radiolabelled glutaminyl cyclase inhibitors |
| WO2014025942A1 (en) * | 2012-08-09 | 2014-02-13 | Emory University | Nmda receptor modulators and uses related thereto |
| GB201308217D0 (en) | 2013-05-08 | 2013-06-12 | Ucl Business Plc | Compounds and their use in therapy |
| WO2015004610A1 (en) | 2013-07-11 | 2015-01-15 | Adamed Sp. Z O.O. | 1,5-dihydropyrrol-2-one derivatives as inhibitors of p53-mdm2/mdm4 protein-protein interaction |
| JP2018501482A (ja) | 2014-12-19 | 2018-01-18 | プロビオドルグ エージー | ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法 |
| US20180104220A1 (en) * | 2015-04-24 | 2018-04-19 | Medshine Discovery Inc. | Imidazole compound |
| WO2018072702A1 (zh) * | 2016-10-20 | 2018-04-26 | 南京明德新药研发股份有限公司 | 一种咪唑类化合物的晶型、盐型及其制备方法 |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| EP3521308B1 (en) | 2018-01-31 | 2024-03-13 | Vivoryon Therapeutics N.V. | Humanized and de-immunized antibodies |
| EP3543231A1 (en) * | 2018-03-19 | 2019-09-25 | ETH Zurich | Compounds for treating cns- and neurodegenerative diseases |
| CN109535140A (zh) * | 2018-12-29 | 2019-03-29 | 常州大学 | 一种基于肟酯与吲哚构建双吲哚取代二氢吡咯酮类衍生物的方法 |
Family Cites Families (468)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2636722A1 (de) * | 1976-08-14 | 1978-02-16 | Goedecke Ag | 3-hydroxy-pyrrolinon-2-derivate |
| JPS57192573A (en) | 1981-05-25 | 1982-11-26 | Hochiki Co | Fire fighting agent |
| JPS6126111A (ja) | 1984-07-16 | 1986-02-05 | Shin Meiwa Ind Co Ltd | 産業用ロボツト |
| JPS6137764A (ja) | 1984-07-31 | 1986-02-22 | Suntory Ltd | 抗プロリルエンドペプチダ−ゼ活性を有する新規生理活性化合物 |
| JPS6152021A (ja) | 1984-08-22 | 1986-03-14 | Fujitsu Ltd | スケルチ回路 |
| JPS6172439A (ja) | 1984-09-18 | 1986-04-14 | Sanyo Electric Co Ltd | デ−タ転送方式 |
| EP0201743B1 (en) | 1985-04-16 | 1992-04-01 | Suntory Limited | Dipeptide derivatives of fatty acids, process for preparing them, pharmaceutical composition and use |
| CA1309805C (en) | 1985-04-16 | 1992-11-03 | Naoki Higuchi | Dipeptide derivative and synthesis and use thereof |
| JPH0623190B2 (ja) | 1985-04-16 | 1994-03-30 | サントリー株式会社 | インヒビタ−活性を有するｎ−アシルピロリジン誘導体及びその製法並びに用途 |
| JPS62114957A (ja) | 1985-11-13 | 1987-05-26 | Suntory Ltd | プロリルエンドペプチダ−ゼ阻害作用を有する新規ピロリジン誘導体およびその製法並びに用途 |
| JPH0714878B2 (ja) | 1985-11-14 | 1995-02-22 | サントリー株式会社 | ピロリジンアミドを有効成分とするプロリルエンドペプチダーゼ阻害剤 |
| JPH0764834B2 (ja) | 1985-11-29 | 1995-07-12 | サントリー株式会社 | プロリルエンドペプチダーゼ阻害活性を有する新規ピロリジンアミド誘導体およびその製法並びに用途 |
| CA1320734C (en) | 1986-02-04 | 1993-07-27 | Suntory Limited | Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same |
| US5198458A (en) | 1986-02-04 | 1993-03-30 | Suntory Limited | Pyrrolidineamide derivatives of acylamino acid and pharmaceutical composition containing the same |
| JPH08806B2 (ja) | 1986-11-18 | 1996-01-10 | サントリー株式会社 | プロリルエンドペプチダ−ゼ阻害作用を有する新規ピロリジンアミド誘導体 |
| DE3786229T2 (de) | 1986-11-20 | 1993-10-07 | Ono Pharmaceutical Co | Prolinalderivate. |
| US5254550A (en) | 1986-11-20 | 1993-10-19 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives and pharmaceutical compositions thereof |
| JPS63162672A (ja) | 1986-12-25 | 1988-07-06 | Ono Pharmaceut Co Ltd | 新規なプロリナ−ル誘導体、それらの製造方法およびそれらを含有する抗健忘症剤 |
| JPH089591B2 (ja) | 1986-12-29 | 1996-01-31 | 小野薬品工業株式会社 | 新規なプロリナール誘導体 |
| DE3783754T2 (de) | 1986-12-29 | 1993-08-05 | Ono Pharmaceutical Co | Prolin-derivate. |
| US5262431A (en) | 1986-12-29 | 1993-11-16 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives and pharmaceutical compositions thereof |
| EP0277588B1 (en) | 1987-02-04 | 1993-03-24 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives |
| DE3875361T2 (de) | 1987-02-23 | 1993-03-25 | Ono Pharmaceutical Co | Thiazolidin-derivate. |
| JPS6442465A (en) | 1987-08-07 | 1989-02-14 | Wakunaga Pharma Co Ltd | N-acylprolylpyrrolidine derivative, production and use thereof |
| JP2649237B2 (ja) | 1988-03-07 | 1997-09-03 | キッセイ薬品工業 株式会社 | チアゾリジン誘導体 |
| US4857524A (en) | 1987-08-08 | 1989-08-15 | Kissei Pharmaceutical Co., Ltd. | Thiazolidine compounds and therapeutic method |
| JP2515558B2 (ja) | 1987-09-10 | 1996-07-10 | 株式会社ヤクルト本社 | 新規なペプチドおよびそれを有効成分とする抗健忘症剤 |
| JPH0742309B2 (ja) | 1987-11-30 | 1995-05-10 | キッセイ薬品工業株式会社 | チアゾリジン誘導体 |
| JPH01250370A (ja) | 1987-12-23 | 1989-10-05 | Zeria Pharmaceut Co Ltd | 新規アミノ酸イミド誘導体、製法ならびに用途 |
| US5053414A (en) | 1988-04-08 | 1991-10-01 | Ono Pharmaceutical Co., Ltd. | Heterocyclic compounds |
| US5328899A (en) | 1988-07-15 | 1994-07-12 | The Salk Institute For Biological Studies | NPY peptide analogs |
| ZA896376B (en) | 1988-08-26 | 1990-05-30 | Merrell Dow Pharma | Neuropeptide y agonists |
| ZA896374B (en) | 1988-08-26 | 1990-05-30 | Merrell Dow Pharma | Neuropeptide y antagonists |
| JP2531989B2 (ja) | 1988-09-14 | 1996-09-04 | 吉富製薬株式会社 | ピリジン化合物 |
| CA2004028C (en) | 1988-12-08 | 1998-09-22 | Motoki Torizuka | Condensed benzene derivative |
| JPH02207070A (ja) | 1989-02-07 | 1990-08-16 | Zeria Pharmaceut Co Ltd | アミノ酸イミド誘導体、それを含有する医薬及び該化合物の製造中間体 |
| EP0419683A4 (en) | 1989-04-13 | 1992-03-11 | Japan Tobacco Inc. | New amino acid derivatives having prolylendopeptidase inhibitor activity |
| DE3939797A1 (de) | 1989-12-01 | 1991-06-06 | Basf Ag | Neue vom neuropeptid y abgeleitete peptide |
| US4985560A (en) | 1990-01-12 | 1991-01-15 | American Home Products Corporation | Pyridazino(4,5-b)indolizines |
| JPH04211648A (ja) | 1990-07-27 | 1992-08-03 | Nippon Kayaku Co Ltd | ケト酸アミド誘導体 |
| JPH03255080A (ja) | 1990-03-05 | 1991-11-13 | Yoshitomi Pharmaceut Ind Ltd | ベンゼン化合物 |
| US4999349A (en) | 1990-03-22 | 1991-03-12 | Bristol-Myers Squibb Co. | BU-4164E - A and B, prolyl endopeptidase inhibitors |
| US5073549A (en) | 1990-03-22 | 1991-12-17 | Bristol-Myers Squibb Company | BU-4164E - A and B, prolyl endopeptidase inhibitors and their methods of use |
| JPH049367A (ja) | 1990-04-26 | 1992-01-14 | Zeria Pharmaceut Co Ltd | アリールアルカノイル誘導体，該化合物の製造中間体及びそれらを含有する医薬 |
| FI925500A7 (fi) | 1990-06-04 | 1992-12-03 | Pfizer | Aromaattisia pyrrolidiini- ja tiatsolidiiniamideja |
| AU643300B2 (en) | 1990-06-07 | 1993-11-11 | Zeria Pharmaceutical Co., Ltd. | Novel arylalkanoylamine derivative and drug containing the same |
| US5506256A (en) | 1990-07-27 | 1996-04-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Proline derivatives possessing prolyl endopeptidase-inhibitory activity |
| JPH05186498A (ja) | 1991-12-27 | 1993-07-27 | Japan Tobacco Inc | プロリン誘導体 |
| EP0468469A2 (en) | 1990-07-27 | 1992-01-29 | Japan Tobacco Inc. | Proline derivatives |
| JPH04235162A (ja) | 1990-08-09 | 1992-08-24 | Zeria Pharmaceut Co Ltd | 新規コハク酸アミド誘導体およびそれを含有する医薬 |
| JPH04208299A (ja) | 1990-11-30 | 1992-07-29 | Ajinomoto Co Inc | プロリルエンドペプチターゼ阻害ペプチド |
| US5104880A (en) | 1991-05-01 | 1992-04-14 | Mayo Foundation For Medical Education And Research | Huperzine a analogs as acetylcholinesterase inhibitors |
| AU1992592A (en) | 1991-05-24 | 1993-01-08 | Pharmavene, Inc. | Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors |
| US5449750A (en) | 1991-06-20 | 1995-09-12 | Snow Brand Milk Products Co., Ltd. | Prolyl endopeptidase inhibitors SNA-115 and SNA-115T, and process for the production and productive strain thereof |
| JP3010795B2 (ja) | 1991-07-04 | 2000-02-21 | 不二製油株式会社 | ペプチドの苦味除去方法 |
| WO1993003034A1 (en) | 1991-07-29 | 1993-02-18 | Warner-Lambert Company | Quinazoline derivatives as acetylcholinesterase inhibitors |
| JPH08501055A (ja) | 1991-12-19 | 1996-02-06 | ガーヴァン インスティチュート オブ メディカル リサーチ | 神経ペプチドチロシンの生物学的機能を抑制する新規な分子 |
| JPH05301826A (ja) | 1991-12-24 | 1993-11-16 | Snow Brand Milk Prod Co Ltd | プロリルエンドペプチダーゼ阻害剤 |
| JPH05201970A (ja) | 1992-01-24 | 1993-08-10 | Japan Tobacco Inc | 新規プロリン誘導体 |
| JP3318622B2 (ja) | 1992-05-27 | 2002-08-26 | 独立行政法人産業技術総合研究所 | プロリルエンドペプチダーゼ阻害剤 |
| GB9212308D0 (en) | 1992-06-10 | 1992-07-22 | Ici Plc | Therapeutic compositions |
| GB9213215D0 (en) | 1992-06-20 | 1992-08-05 | Wellcome Found | Peptides |
| JPH06116284A (ja) | 1992-10-02 | 1994-04-26 | Yamanouchi Pharmaceut Co Ltd | 新規ペプチド |
| KR100262254B1 (ko) | 1992-10-05 | 2000-07-15 | 나카히로 마오미 | 피리미딘 화합물 |
| US5260286A (en) | 1992-10-16 | 1993-11-09 | Japan Tobacco, Inc. | 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists |
| EP0670309A1 (en) | 1992-11-20 | 1995-09-06 | Japan Tobacco Inc. | Compound with prolyl endopeptidase inhibitor activity and pharmaceutical use thereof |
| US5354758A (en) | 1992-12-16 | 1994-10-11 | Japan Tobacco Inc. | Benzomorphans useful as NMDA receptor antagonists |
| JPH06192298A (ja) | 1992-12-24 | 1994-07-12 | Mitsui Toatsu Chem Inc | 新規機能性ペプチド |
| DE4326465A1 (de) | 1993-01-20 | 1995-02-09 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| JPH06234693A (ja) | 1993-02-09 | 1994-08-23 | Snow Brand Milk Prod Co Ltd | 新規イソテトラセノン系物質及びその製造法 |
| FR2701480B1 (fr) | 1993-02-15 | 1995-05-24 | Sanofi Elf | Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
| EP0611769A1 (en) | 1993-02-16 | 1994-08-24 | Merrell Dow Pharmaceuticals Inc. | Silylated acetylcholinesterase inhibitors |
| AU4982293A (en) | 1993-03-02 | 1994-09-26 | Fujisawa Pharmaceutical Co., Ltd. | Novel heterocyclic compound |
| FR2702150B1 (fr) | 1993-03-03 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application de dérivés de 2H-1,2-4-benzothiadiazine-3(4H)-one-1,1-dioxyde comme antagonistes non compétitifs du récepteur NMDA. |
| FR2703050B1 (fr) | 1993-03-24 | 1995-04-28 | Adir | Nouveaux dérivés bicycliques azotés, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| EP0627400A1 (en) | 1993-06-04 | 1994-12-07 | Merrell Dow Pharmaceuticals Inc. | Aromatic acetylcholinesterase inhibitors |
| CA2165200A1 (en) | 1993-06-18 | 1995-01-05 | Ambikaipakan Balasubramaniam | Neuropeptide y antagonists and agonists |
| AU6983894A (en) | 1993-06-30 | 1995-01-24 | Zeria Pharmaceutical Co., Ltd. | Thiazolidine derivative and medicine containing the same |
| FR2707643B1 (fr) | 1993-07-16 | 1995-08-11 | Rhone Poulenc Rorer Sa | Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant. |
| FR2707645B1 (fr) | 1993-07-16 | 1995-08-11 | Rhone Poulenc Rorer Sa | Dérivés d'imidazo[1,2-a]pirazine-4-one, leur préparation et les médicaments les contenant. |
| EP0709373B1 (en) | 1993-07-23 | 2001-10-17 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Pyrrolidine derivative |
| FR2711993B1 (fr) | 1993-11-05 | 1995-12-01 | Rhone Poulenc Rorer Sa | Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation. |
| NZ276600A (en) | 1993-12-02 | 1997-09-22 | Merrell Pharma Inc | 2-acylpyrrolidines; compounds, preparation and pharmaceutical compositions |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| FR2717805B1 (fr) | 1994-03-28 | 1996-05-10 | Rhone Poulenc Rorer Sa | Dérivés de 5H-indeno[1,2-b]pyrazine-2,3-dione, leur préparation et les médicaments les contenant . |
| FR2717813B1 (fr) | 1994-03-28 | 1996-05-10 | Rhone Poulenc Rorer Sa | Dérivés d'imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant . |
| FR2717811B1 (fr) | 1994-03-28 | 1996-04-26 | Rhone Poulenc Rorer Sa | Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant. |
| FR2717812B1 (fr) | 1994-03-28 | 1996-05-10 | Rhone Poulenc Rorer Sa | Indeno[1,2-e]pyrazine-4-ones, leur préparation et les médicaments les contenant. |
| JPH07267988A (ja) | 1994-03-31 | 1995-10-17 | Yamanouchi Pharmaceut Co Ltd | 新規ペプチド |
| GB9410320D0 (en) | 1994-05-24 | 1994-07-13 | Fisons Corp | Novel therapeutic method |
| GB9418443D0 (en) | 1994-09-13 | 1994-11-02 | Pfizer Ltd | Therapeutic agents |
| EP0895781A3 (en) | 1994-10-20 | 1999-07-07 | Eli Lilly And Company | Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins |
| US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
| US5663192A (en) | 1994-10-20 | 1997-09-02 | Eli Lilly And Company | Heterocyclic neuropeptide Y receptor antagonists |
| FR2726275B1 (fr) | 1994-11-02 | 1996-12-06 | Rhone Poulenc Rorer Sa | Spiro heterocycle-imidazo(1,2-a)indeno(1,2-e)pyrazine)-4'- ones, leur preparation et les medicaments les contenants |
| IL116584A0 (en) | 1994-12-29 | 1996-03-31 | Res Dev Foundation | Novel flavin adenine dinucleotide analogue inhibitors of monoamine oxidase |
| US5691368A (en) | 1995-01-11 | 1997-11-25 | Hoechst Marion Roussel, Inc. | Substituted oxazolidine calpain and/or cathepsin B inhibitors |
| GB9500601D0 (en) | 1995-01-12 | 1995-03-01 | Wellcome Found | Modified peptides |
| US5552411A (en) | 1995-05-26 | 1996-09-03 | Warner-Lambert Company | Sulfonylquinolines as central nervous system and cardiovascular agents |
| US5554621A (en) | 1995-06-07 | 1996-09-10 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives |
| US5635503A (en) | 1995-06-07 | 1997-06-03 | Bristol-Myers Squibb Company | Dihydropyridine npy antagonists: piperazine derivatives |
| IL117997A0 (en) | 1995-06-07 | 1996-10-31 | Pfizer | Neuropeptide Y1 specific ligands |
| US5668151A (en) | 1995-06-07 | 1997-09-16 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: piperidine derivatives |
| JP3727383B2 (ja) | 1995-07-31 | 2005-12-14 | 月桂冠株式会社 | プロリルエンドペプチダーゼ阻害剤 |
| IL120724A0 (en) | 1995-09-01 | 1997-08-14 | Lilly Co Eli | Indolyl neuropeptide Y receptor antagonists |
| AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| ES2100129B1 (es) | 1995-10-11 | 1998-02-16 | Medichem Sa | Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion. |
| DE19544687A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE19544686A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE19544685A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| AU1328197A (en) | 1995-12-01 | 1997-06-19 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
| AU7626496A (en) | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Heteroaryl compounds |
| WO1997020822A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Quinazolin-2,4-diazirines as npy receptor antagonist |
| AU7692996A (en) | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Receptor antagonists |
| AU7692696A (en) | 1995-12-01 | 1997-06-27 | Novartis Ag | Heteroaryl derivatives |
| JPH09157253A (ja) | 1995-12-12 | 1997-06-17 | Yamanouchi Pharmaceut Co Ltd | 新規アミノ酸誘導体 |
| ZA9610736B (en) | 1995-12-22 | 1997-06-27 | Warner Lambert Co | 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists |
| ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| ZA9610745B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| EP0871442A1 (en) | 1996-01-09 | 1998-10-21 | Eli Lilly And Company | Benzimidzolyl neuropeptide y receptor antagonists |
| GB9605027D0 (en) | 1996-03-09 | 1996-05-08 | Pfizer Ltd | Quinoxalinediones |
| US5662723A (en) | 1996-03-22 | 1997-09-02 | Libbey Glass Inc. | Apparatus and method for forming a decorative pattern on glassware having an edge |
| JP4109718B2 (ja) | 1996-04-12 | 2008-07-02 | アベンティス・ファーマスーティカルズ・インコーポレイテッド | アセチルコリンエステラーゼ阻害剤および鎮痛剤としてのイサチン誘導体 |
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| AU3295297A (en) | 1996-06-04 | 1998-01-05 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5) |
| EP0942751B1 (en) | 1996-07-05 | 2002-09-25 | The WWK Trust | Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter |
| WO1998003493A1 (en) | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands |
| ES2197354T3 (es) | 1996-07-23 | 2004-01-01 | Neurogen Corporation | Derivados de bencilamina sustituidos con amido y amino; una nueva clase de ligandos especificos del neuropeptido y1. |
| ATE230403T1 (de) | 1996-07-23 | 2003-01-15 | Neurogen Corp | Einige amido- und ammo- substituierte benzylaminderivate: eine neue klasse von neuropeptid y1 spezifische ligande |
| WO1998005337A1 (en) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| WO1998006703A1 (en) | 1996-08-14 | 1998-02-19 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as mcp-1 antagonists |
| AU4159297A (en) | 1996-08-23 | 1998-03-06 | Agouron Acquisition Corp. | Neuropeptide-y ligands |
| JP3880664B2 (ja) | 1996-09-04 | 2007-02-14 | 月桂冠株式会社 | プロリルエンドペプチダーゼ阻害ペプチド |
| AU4424697A (en) | 1996-09-11 | 1998-04-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity |
| AU4944297A (en) | 1996-10-08 | 1998-05-05 | Novartis Ag | Modulation of apoptosis |
| FR2754709B1 (fr) | 1996-10-23 | 1999-03-05 | Sanofi Sa | Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition |
| US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| AU5716898A (en) | 1997-01-08 | 1998-08-03 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
| AU6417198A (en) | 1997-03-13 | 1998-09-29 | Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency | Cytoprotective agents comprising monoamine oxidase inhibitors |
| CA2286660A1 (en) | 1997-04-16 | 1998-10-22 | Arqule, Inc. | Synthesis and use of .alpha.-ketoamide derivatives and arrays |
| CA2289190A1 (en) | 1997-05-07 | 1998-11-12 | Algos Pharmaceutical Corporation | Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain |
| WO1998050075A1 (en) | 1997-05-07 | 1998-11-12 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with nmda-blockers for treating pain |
| KR100630506B1 (ko) | 1997-06-30 | 2006-09-29 | 메르츠 파마 게엠베하 운트 코. 카가아 | Ｎｍｄａ 수용체 길항물질로서의 1-아미노-알킬시클로헥산 화합물, 이를 함유하는 제약학적 조성물 및 이것으로 치료하는 방법 |
| GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| GB9716879D0 (en) | 1997-08-08 | 1997-10-15 | Shire Int Licensing Bv | Treatment of attention deficit disorders |
| WO1999007413A1 (en) | 1997-08-11 | 1999-02-18 | Algos Pharmaceutical Corporation | Substance p inhibitors in combination with nmda-blockers for treating pain |
| SE9703376D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
| SE9703414D0 (sv) | 1997-09-23 | 1997-09-23 | Astra Ab | New compounds |
| EP2583675A1 (en) | 1998-02-02 | 2013-04-24 | Trustees Of Tufts College | Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism |
| JP2002506075A (ja) | 1998-03-09 | 2002-02-26 | フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ | セリンペプチダーゼ調節剤 |
| US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
| GB9805561D0 (en) | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
| US6541208B1 (en) | 1998-03-17 | 2003-04-01 | University Of Maryland Biotechnology Institute | Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia |
| DE19812331A1 (de) | 1998-03-20 | 1999-09-23 | Merck Patent Gmbh | Piperidinderivate |
| US6054451A (en) | 1998-04-21 | 2000-04-25 | Algos Pharmaceutical Corporation | Analgesic composition and method for alleviating pain |
| WO1999057119A1 (en) | 1998-05-04 | 1999-11-11 | Neotherapeutics, Inc. | Novel dopamine-like 9-substituted hypoxanthine and methods of use |
| US6303617B1 (en) | 1998-05-04 | 2001-10-16 | Neotherapeutics, Inc. | Serotonin-like 9-substituted hypoxanthine and methods of use |
| DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
| PE20000728A1 (es) | 1998-06-26 | 2000-08-21 | Cocensys Inc | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda |
| US6262081B1 (en) | 1998-07-10 | 2001-07-17 | Dupont Pharmaceuticals Company | Composition for and method of treating neurological disorders |
| DE19834591A1 (de) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
| US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| IL125809A (en) | 1998-08-17 | 2005-08-31 | Finetech Lab Ltd | Process and intermediates for production of donepezil and related compounds |
| IT1304904B1 (it) | 1998-09-11 | 2001-04-05 | Eisai Co Ltd | Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche |
| AU6059699A (en) | 1998-09-23 | 2000-04-10 | Regents Of The University Of California, The | Synthetic peptides, conjugation reagents and methods |
| WO2000023057A2 (en) | 1998-10-16 | 2000-04-27 | Janssen Pharmaceutica N.V. | Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
| CA2351224A1 (en) | 1998-11-12 | 2000-05-25 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with nmda-blockers for treating pain |
| AU1738800A (en) | 1998-11-23 | 2000-06-13 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
| WO2000030674A1 (en) | 1998-11-26 | 2000-06-02 | Ferring Bv | Neuropeptide y y4 agents in the treatment of reproductive disorders |
| AU2354400A (en) | 1998-12-11 | 2000-06-26 | Bonnie Davis | Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis |
| GB9902452D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902459D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902455D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902461D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| EP1163220A1 (en) | 1999-03-23 | 2001-12-19 | Sumitomo Pharmaceuticals Company, Limited | Tricyclic indole-2-carboxylic acid compound used as nmda receptor antagonist |
| US6121311A (en) | 1999-04-28 | 2000-09-19 | Japan Tobacco Inc. | Method for treating cocainism |
| HK1041263A1 (zh) | 1999-05-05 | 2002-07-05 | Ortho-Mcneil Pharmaceutical, Inc. | 可用於治疗肥胖和其他疾病的3a，4，5，9b-四氢-1h-苯并[e]吲-2-基胺衍生的神经肽y受体配体 |
| JP3148739B2 (ja) | 1999-05-19 | 2001-03-26 | ドーマー株式会社 | プロリルエンドペプチダーゼ阻害剤 |
| US6110949A (en) | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6107317A (en) | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6172081B1 (en) | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
| AU6053900A (en) | 1999-06-25 | 2001-01-31 | Morris Notelovitz | Compositions for treating or preventing neurodegeneration and cognitive decline |
| DE19936521A1 (de) | 1999-08-06 | 2001-02-15 | Gruenenthal Gmbh | Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate |
| DE19936719A1 (de) | 1999-08-06 | 2001-02-15 | Gruenenthal Gmbh | Substituierte 1,5-Dihydropyrrol-2-on-Derivate |
| EP1078632A1 (en) | 1999-08-16 | 2001-02-28 | Sanofi-Synthelabo | Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity |
| DE19940130A1 (de) | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
| TWI283577B (en) | 1999-10-11 | 2007-07-11 | Sod Conseils Rech Applic | Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof |
| UA72558C2 (uk) | 1999-11-01 | 2005-03-15 | Мерц Фарма Гмбх Унд Ко. Кгаа | 1-аміноалкілциклогексанові антагоністи рецептора nmda |
| JP2003535034A (ja) | 1999-11-12 | 2003-11-25 | ギルフォード ファーマシューティカルズ インコーポレイテッド | ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法 |
| GB9928330D0 (en) | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
| JP2003520266A (ja) | 2000-01-24 | 2003-07-02 | メルク シャープ エンド ドーム リミテッド | γ−セクレターゼ阻害薬 |
| WO2001055105A1 (en) | 2000-01-24 | 2001-08-02 | Novo Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
| GB0005251D0 (en) | 2000-03-03 | 2000-04-26 | Merck Sharp & Dohme | Therapeutic compounds |
| WO2001066096A2 (en) | 2000-03-06 | 2001-09-13 | Immune Network Ltd. | Compositions for prevention and treatment of dementia |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| DE60124080T2 (de) | 2000-03-23 | 2007-03-01 | Elan Pharmaceuticals, Inc., San Francisco | Verbindungen und verfahren zur behandlung der alzheimerschen krankheit |
| US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| GB0008710D0 (en) | 2000-04-07 | 2000-05-31 | Merck Sharp & Dohme | Therapeutic compounds |
| EP1285656A4 (en) | 2000-04-13 | 2006-07-12 | Eisai Co Ltd | ACETYLCHOLINESTERASE HEMMER CONTAINING 1-BENZYLPYRIDINIUM SALT |
| GB0010188D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| MXPA02009659A (es) | 2000-04-26 | 2003-03-10 | Warner Lambert Co | Derivado de ciclohexilamina como subtipo de los antagonistas del receptor selectivo nmda. |
| US20010036949A1 (en) | 2000-05-09 | 2001-11-01 | Coe Jotham Wadsworth | Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| JP2003535073A (ja) | 2000-06-01 | 2003-11-25 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | サブタイプ選択性ｎｍｄａレセプター拮抗物質としてのシクロヘキシルアミン誘導体 |
| AU2001263130A1 (en) | 2000-06-06 | 2001-12-17 | Warner Lambert Company | Bicyclic cyclohexylamines and their use as nmda receptor antagonists |
| DE60125541T2 (de) | 2000-06-22 | 2007-10-11 | Pharmos Corp. | Neue nicht psychotropische cannabinoide |
| GB0015488D0 (en) | 2000-06-23 | 2000-08-16 | Merck Sharp & Dohme | Therapeutic agents |
| US6713276B2 (en) | 2000-06-28 | 2004-03-30 | Scios, Inc. | Modulation of Aβ levels by β-secretase BACE2 |
| US6686449B2 (en) | 2000-06-30 | 2004-02-03 | Pharmacia & Upjohn Company | Mutant presenilin 1 polypeptides |
| JP2004502664A (ja) | 2000-06-30 | 2004-01-29 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病処置用化合物 |
| AU2001268958B2 (en) | 2000-07-04 | 2006-03-09 | Novo Nordisk A/S | Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv |
| GB0016681D0 (en) | 2000-07-06 | 2000-08-23 | Merck Sharp & Dohme | Therapeutic compounds |
| US6556971B1 (en) | 2000-09-01 | 2003-04-29 | Snap-On Technologies, Inc. | Computer-implemented speech recognition system training |
| US20040236450A1 (en) | 2000-09-25 | 2004-11-25 | Motorwiz, Inc. | Model-based machine diagnostics and prognostics using theory of noise and communications |
| US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| CA2427206C (en) | 2000-11-02 | 2011-06-28 | Merck Sharp & Dohme Limited | Sulfamides as gamma-secretase inhibitors |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| US6670364B2 (en) | 2001-01-31 | 2003-12-30 | Telik, Inc. | Antagonists of MCP-1 function and methods of use thereof |
| TWI245761B (en) | 2001-03-01 | 2005-12-21 | Telik Inc | Antagonists of MCP-1 function and methods of use thereof |
| US7375136B2 (en) | 2001-03-08 | 2008-05-20 | Emory University | pH-dependent NMDA receptor antagonists |
| US6649196B2 (en) | 2001-03-12 | 2003-11-18 | Mayo Foundation For Medical Education And Research | Methods of reducing β-amyloid polypeptides |
| US6677365B2 (en) | 2001-04-03 | 2004-01-13 | Telik, Inc. | Antagonists of MCP-1 function and methods of use thereof |
| US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| SI20922A (sl) | 2001-05-18 | 2002-12-31 | Krka Tovarna Zdravil, D.D., Novo Mesto | Monoklonsko protitelo, ki nevtralizira aktivnost katepsina B, in njegove uporabe |
| US6562783B2 (en) | 2001-05-30 | 2003-05-13 | Neurologic, Inc. | Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors |
| MXPA03011046A (es) | 2001-06-01 | 2004-06-25 | Elan Pharm Inc | Hidroxialquilaminas. |
| CA2450579A1 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| ES2257555T3 (es) | 2001-06-20 | 2006-08-01 | MERCK & CO., INC. | Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes. |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| DE10150203A1 (de) | 2001-10-12 | 2003-04-17 | Probiodrug Ag | Peptidylketone als Inhibitoren der DPIV |
| EP1399470A2 (en) | 2001-06-27 | 2004-03-24 | Probiodrug AG | Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| JP4357293B2 (ja) | 2001-06-27 | 2009-11-04 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類 |
| CN1723196A (zh) | 2001-06-27 | 2006-01-18 | 史密丝克莱恩比彻姆公司 | 作为二肽酶抑制剂的氟代吡咯烷 |
| DE10154689A1 (de) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
| ATE380175T1 (de) | 2001-06-27 | 2007-12-15 | Smithkline Beecham Corp | Pyrrolidine als dipeptidyl peptidase inhibitoren |
| BR0210721A (pt) | 2001-06-27 | 2004-07-20 | Elan Pharm Inc | Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição |
| RU2003105463A (ru) | 2001-06-27 | 2004-11-27 | Пробиодруг Аг (De) | Пептидные структуры, пригодные для конкурентного модулирования катализа, осуществляемого дипептидилпептидазой iv |
| DE60225556D1 (de) | 2001-07-03 | 2008-04-24 | Novo Nordisk As | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| CA2453383C (en) | 2001-07-24 | 2010-04-06 | Richter Gedeon Vegyeszeti Gyar Rt | Piperidine derivatives as nmda receptor antagonists |
| US6948038B2 (en) * | 2001-07-24 | 2005-09-20 | Microsoft Corporation | System and method for backing up and restoring data |
| US7122675B2 (en) | 2001-08-03 | 2006-10-17 | Schering Corporation | Gamma secretase inhibitors |
| AR034390A1 (es) | 2001-08-03 | 2004-02-25 | Schering Corp | Derivados de 1-sulfonil-tetrahidro quinolinas sustituidas, composiciones farmaceuticas y el uso de las mismas para la elaboracion de medicamentos como inhibidores de la gama secretasa |
| CA2459146A1 (en) | 2001-08-30 | 2003-03-13 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
| KR20040033048A (ko) | 2001-09-14 | 2004-04-17 | 미츠비시 웰파마 가부시키가이샤 | 티아졸리딘 유도체 및 이의 약학적 용도 |
| AU2002331311A1 (en) | 2001-09-19 | 2003-04-01 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
| KR20040048936A (ko) * | 2001-10-03 | 2004-06-10 | 유씨비 소시에떼아노님 | 피롤리디논 유도체 |
| GB0125445D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
| JP4547152B2 (ja) | 2001-10-23 | 2010-09-22 | オクラホマ メディカル リサーチ ファウンデーション | β−セクレターゼ阻害剤および使用方法 |
| GB0125446D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Novel anti-diabetic agents |
| US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| WO2003037376A1 (fr) | 2001-11-02 | 2003-05-08 | Kensuke Egashira | Prophylactiques et/ou remedes pour le traitement de l'arteriosclerose apres transplantation dans le cas de rejet de greffe |
| BR0214295A (pt) | 2001-11-19 | 2004-11-09 | Elan Pharm Inc | Composto, método para tratar um paciente que tem ou prevenir um paciente de adquirir uma doença ou condição, e, método para produzir um composto |
| EP2316470A3 (en) | 2001-11-26 | 2011-08-24 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
| IL162533A0 (en) | 2001-12-19 | 2005-11-20 | Atherogenics Inc | Chalcone derivatives and their use to treat diseases |
| AU2002360732A1 (en) | 2001-12-26 | 2003-07-24 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
| US6727261B2 (en) | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
| AU2003235799A1 (en) | 2002-01-08 | 2003-07-24 | Nordic Bioscience A/S | Modulation of iamt (pimt or pcmt) in immune system |
| JP2005516967A (ja) | 2002-01-18 | 2005-06-09 | ザ ジェネティクス カンパニー インコーポレーティッド | β−セクレターゼインヒビター |
| TW200302717A (en) | 2002-02-06 | 2003-08-16 | Schering Corp | Novel gamma secretase inhibitors |
| US20040171614A1 (en) | 2002-02-06 | 2004-09-02 | Schering-Plough Corporation | Novel gamma secretase inhibitors |
| JP4359146B2 (ja) | 2002-02-13 | 2009-11-04 | エフ．ホフマン−ラ ロシュ アーゲー | 新規なピリジン−およびピリミジン−誘導体 |
| ES2252656T3 (es) | 2002-02-13 | 2006-05-16 | F. Hoffmann-La Roche Ag | Nuevos derivados de piridina y quinolina. |
| HUP0200849A2 (hu) | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
| CA2478389A1 (en) | 2002-03-25 | 2003-10-09 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| EP1491531B1 (en) | 2002-03-29 | 2007-12-26 | Eisai R&D Management Co., Ltd. | (1-indanone)-(1,2,3,6-tetrahydropyridine) derivative |
| DE60329995D1 (de) | 2002-04-24 | 2009-12-24 | Hiroshi Mori | Gamma-sekretase-inhibitoren |
| CN1649845A (zh) | 2002-04-26 | 2005-08-03 | 先灵公司 | 蝇蕈碱拮抗剂 |
| US7205336B2 (en) | 2002-05-17 | 2007-04-17 | Merck & Co., Inc. | β-secretase inhibitors |
| PT1509232E (pt) | 2002-05-31 | 2009-01-07 | Lundbeck & Co As H | Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer |
| WO2003101449A2 (en) | 2002-06-04 | 2003-12-11 | Pfizer Products Inc. | Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof |
| JP2005533771A (ja) | 2002-06-04 | 2005-11-10 | ファイザー・プロダクツ・インク | ジペプチジルペプチダーゼｉｖ阻害剤としてのフッ素化環式アミド |
| AU2003241960B2 (en) | 2002-06-06 | 2009-07-30 | Eisai R&D Management Co., Ltd. | Novel fused imidazole derivative |
| AU2003279355A1 (en) | 2002-06-19 | 2004-01-06 | Surface Specialties, S.A. | Semi-gloss powder coating compositions |
| AU2003248259A1 (en) | 2002-07-10 | 2004-02-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel azetidine derivative or salt thereof |
| US7208498B2 (en) | 2002-07-15 | 2007-04-24 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| WO2004009062A2 (en) | 2002-07-19 | 2004-01-29 | Khalid Iqbal | NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau |
| US7557137B2 (en) | 2002-08-05 | 2009-07-07 | Bristol-Myers Squibb Company | Gamma-lactams as beta-secretase inhibitors |
| ES2339112T3 (es) | 2002-08-21 | 2010-05-17 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | 8-(3-amino-piperidin-1-il)-xantinas,su preparacion y su uso como medicamentos. |
| DE10238477A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10238470A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2004024921A1 (ja) | 2002-09-12 | 2004-03-25 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | ヒト抗ヒトｍｃｐ−１抗体及び該抗体フラグメント |
| CA2768674A1 (en) | 2002-09-19 | 2004-04-01 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
| WO2004026851A1 (en) | 2002-09-20 | 2004-04-01 | Axys Pharmaceuticals, Inc. | 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| GB0223039D0 (en) | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| GB0223038D0 (en) | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| ATE370141T1 (de) | 2002-10-07 | 2007-09-15 | Merck & Co Inc | Antidiabetische heterocyclische beta- aminoverbindungen als inhibitoren von dipeptidylpeptidase |
| AU2003269850A1 (en) | 2002-10-08 | 2004-05-04 | Novo Nordisk A/S | Hemisuccinate salts of heterocyclic dpp-iv inhibitors |
| GB0223494D0 (en) | 2002-10-09 | 2002-11-13 | Neuropharma Sa | Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease |
| CA2502269C (en) | 2002-10-18 | 2009-12-22 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| TW200418446A (en) | 2002-10-24 | 2004-10-01 | Merz Pharma Gmbh & Co Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| US20040082543A1 (en) | 2002-10-29 | 2004-04-29 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain |
| WO2004041795A1 (en) | 2002-10-30 | 2004-05-21 | Guilford Pharmaceuticals Inc. | Novel inhibitors of dipeptidyl peptidase iv |
| WO2004039773A2 (en) | 2002-10-30 | 2004-05-13 | Nordic Bioscience A/S | Coumpounds modulating the activity of gapdh and/or iamt |
| GB0225474D0 (en) | 2002-11-01 | 2002-12-11 | Merck Sharp & Dohme | Therapeutic agents |
| CA2504735C (en) | 2002-11-07 | 2009-06-23 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| ATE443043T1 (de) | 2002-11-12 | 2009-10-15 | Merck & Co Inc | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer |
| AU2002952946A0 (en) | 2002-11-27 | 2002-12-12 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| WO2004050022A2 (en) | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| WO2004056727A2 (en) | 2002-12-19 | 2004-07-08 | Atherogenics, Inc. | Process of making chalcone derivatives |
| CA2508947A1 (en) | 2002-12-20 | 2004-07-15 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| WO2004062625A2 (en) | 2003-01-07 | 2004-07-29 | Merck & Co., Inc. | Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease |
| EP1589969A4 (en) | 2003-01-17 | 2008-08-13 | Merck & Co Inc | 3-AMINO-4-PHENYLBUTANEAN DERIVATEALS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES |
| CA2513684A1 (en) | 2003-01-31 | 2004-08-19 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| EP1592684B1 (en) | 2003-02-04 | 2008-07-30 | F. Hoffmann-La Roche Ag | Malonamide derivatives as gamma-secretase inhibitors |
| WO2004071454A2 (en) | 2003-02-13 | 2004-08-26 | Guilford Pharmaceuticals Inc. | Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv |
| CA2516259A1 (en) | 2003-02-18 | 2004-09-02 | Roskamp Research, Llc | Anti-angiogenic and anti-tumoral properties of beta and gamma secretase inhibitors |
| WO2004076433A1 (en) | 2003-02-28 | 2004-09-10 | Aic | Dipeptidyl peptidase inhibitors |
| WO2004076434A1 (en) | 2003-02-28 | 2004-09-10 | Aic | Dipeptidyl peptidase inhibitors |
| EP1454627A1 (en) | 2003-03-06 | 2004-09-08 | MyoContract Ltd. | Alpha-Keto carbonyl calpain inhibitors |
| WO2004084830A2 (en) | 2003-03-21 | 2004-10-07 | Buck Institute | Method for treating alzheimer’s dementia |
| US20040191334A1 (en) | 2003-03-24 | 2004-09-30 | Pang-Chui Shaw | Use of transhinone derivates as cholinesterase inhibitors in treating related diseases |
| CA2518465A1 (en) | 2003-03-25 | 2004-10-14 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| NZ542690A (en) | 2003-03-28 | 2009-04-30 | Acadia Pharm Inc | Muscarinic M1 receptor agonists for pain management |
| ATE481103T1 (de) | 2003-04-09 | 2010-10-15 | Wyeth Llc | Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten |
| GB0308382D0 (en) | 2003-04-10 | 2003-05-21 | Univ Cambridge Tech | Therapeutic methods and means |
| GB0308318D0 (en) | 2003-04-10 | 2003-05-14 | Merck Sharp & Dohme | Therapeutic agents |
| WO2004089362A1 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | 2-cyanopyrroles and their analogues as ddp-iv inhibitors |
| WO2004098591A2 (en) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases |
| US8338120B2 (en) * | 2003-05-05 | 2012-12-25 | Probiodrug Ag | Method of treating inflammation with glutaminyl cyclase inhibitors |
| EP1622870A2 (en) | 2003-05-05 | 2006-02-08 | Prosidion Ltd. | Glutaminyl based dp iv-inhibitors |
| CN1784220B (zh) | 2003-05-05 | 2011-08-03 | 前体生物药物股份公司 | 谷氨酰胺酰基和谷氨酸环化酶效应物的应用 |
| US7732162B2 (en) * | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| EP1961416B1 (en) * | 2003-05-05 | 2013-01-23 | Probiodrug AG | Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis. |
| AU2003902260A0 (en) | 2003-05-09 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| WO2004101562A2 (en) | 2003-05-13 | 2004-11-25 | Schering Corporation | Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors |
| US7560455B2 (en) | 2003-05-14 | 2009-07-14 | Merck & Co., Inc. | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| JP2007511467A (ja) | 2003-05-14 | 2007-05-10 | タケダ サン ディエゴ インコーポレイテッド | ジペプチジルペプチダーゼインヒビター |
| MXPA05012323A (es) | 2003-05-16 | 2006-01-30 | Merck Sharp & Dohme | Sulfonamidas ciclicas para la inhibicion de gama-secretasa. |
| EP2260844A1 (en) | 2003-05-27 | 2010-12-15 | Merz Pharma GmbH & Co. KGaA | Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders |
| AU2003902828A0 (en) | 2003-06-05 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| CN1798556A (zh) | 2003-06-06 | 2006-07-05 | 麦克公司 | 作为治疗或者预防糖尿病的二肽基肽酶抑制剂的稠合吲哚 |
| AU2003902946A0 (en) | 2003-06-12 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| CN1809544A (zh) | 2003-06-17 | 2006-07-26 | 麦克公司 | 作为二肽基肽酶抑制剂用于治疗或预防糖尿病的环己基甘氨酸衍生物 |
| WO2005000848A1 (en) | 2003-06-20 | 2005-01-06 | F. Hoffmann-La Roche Ag | Pyrido` 2, 1-a - isoquinoline derivatives as dpp-iv inhibitors |
| ATE437876T1 (de) | 2003-06-20 | 2009-08-15 | Hoffmann La Roche | Hexahydropyridoisochinoline als dpp-iv- inhibitoren |
| JP2007516207A (ja) | 2003-06-30 | 2007-06-21 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病の治療のためのＮ−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤 |
| AU2004255191A1 (en) | 2003-07-01 | 2005-01-20 | Merck & Co., Inc. | Phenylcarboxylate beta-secretase inhibitors for the treatment of Alzheimer's disease |
| WO2005007614A1 (en) | 2003-07-03 | 2005-01-27 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services 6011 | Monoamine oxidase inhibitors |
| DE602004027048D1 (de) | 2003-07-16 | 2010-06-17 | Resverlogix Inc | Verbindungen und methoden für das downregulating der effekte von tgf-beta |
| EP1671129A1 (en) | 2003-07-21 | 2006-06-21 | Angiogenetics Sweden AB | Compounds and methods for promoting angiogenesis by using a gamma-secretase inhibitor or inhibiting the gamma-secretase pathway |
| EP1660058A2 (en) | 2003-07-28 | 2006-05-31 | Merz Pharma GmbH & Co. KGaA | The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity |
| US7259160B2 (en) | 2003-07-31 | 2007-08-21 | Merck & Co., Inc. | Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| GB0318447D0 (en) | 2003-08-05 | 2003-09-10 | Merck Sharp & Dohme | Therapeutic agents |
| KR20060041309A (ko) | 2003-08-13 | 2006-05-11 | 다케다 야쿠힌 고교 가부시키가이샤 | ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도 |
| CA2535337A1 (en) | 2003-08-14 | 2005-03-03 | Merck & Co., Inc. | Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease |
| WO2005023762A1 (en) | 2003-09-04 | 2005-03-17 | Abbott Laboratories | Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
| EP1697342A2 (en) | 2003-09-08 | 2006-09-06 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| EP1699777B1 (en) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| PE20050948A1 (es) | 2003-09-09 | 2005-12-16 | Japan Tobacco Inc | Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv |
| GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| WO2005027882A1 (en) | 2003-09-22 | 2005-03-31 | Bionetworks Gmbh | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss |
| US7514459B2 (en) | 2003-09-24 | 2009-04-07 | Merck Sharp & Dohme Ltd. | Gamma-secretase inhibitors |
| EP1673078B1 (en) | 2003-10-03 | 2008-05-28 | Merck & Co., Inc. | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease |
| BR0318533A (pt) | 2003-10-06 | 2006-09-12 | Torrent Pharmaceuticals Ltd | azolidinacarbonitrilas e seu uso como inibidores de dpp-iv |
| SI1673347T1 (sl) | 2003-10-06 | 2015-10-30 | F. Hoffmann - La Roche Ag | Substituirani derivati dibenzo-azepina in benzo-diazepina, ki so uporabni kot inhibitorji gama-sekretaze |
| WO2005035522A1 (en) | 2003-10-08 | 2005-04-21 | Pfizer Japan, Inc. | 1-‘2-(4-hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists |
| BRPI0415409A (pt) | 2003-10-15 | 2006-12-05 | Probiodrug Ag | uso de efetuadores de ciclases de glutaminila e glutamato |
| GB0324236D0 (en) | 2003-10-16 | 2003-11-19 | Astrazeneca Ab | Chemical compounds |
| EP1675591B1 (en) | 2003-10-16 | 2011-08-10 | NeuroSearch A/S | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor |
| TW200519105A (en) | 2003-10-20 | 2005-06-16 | Lg Life Science Ltd | Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
| WO2005079779A1 (en) | 2003-10-22 | 2005-09-01 | Merz Pharma Gmbh & Co. Kgaa | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES |
| EP1824846A2 (en) | 2003-11-03 | 2007-08-29 | Probiodrug AG | Novel compounds for the treatment of neurological disorders |
| AU2004290499C1 (en) * | 2003-11-03 | 2011-02-24 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| US20050171112A1 (en) * | 2003-11-03 | 2005-08-04 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| US7667044B2 (en) * | 2003-11-03 | 2010-02-23 | Probiodrug Ag | Compounds for the treatment of neurological disorders |
| AU2004286857A1 (en) | 2003-11-04 | 2005-05-19 | Merck & Co., Inc. | Fused phenylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| EP1685142B1 (en) | 2003-11-11 | 2008-01-09 | F. Hoffmann-La Roche Ag | Phosphinic acid derivatives, beta-secretase inhibitors for the treatment of alzheimer's disease |
| SG134333A1 (en) | 2003-11-12 | 2007-08-29 | Phenomix Corp | Heterocyclic boronic acid compounds |
| ATE517861T1 (de) | 2003-11-24 | 2011-08-15 | Merck Sharp & Dohme | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit |
| DE10355304A1 (de) | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| UY28650A1 (es) | 2003-12-05 | 2005-02-28 | Forest Laboratories | Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta |
| EP1541148A1 (en) | 2003-12-09 | 2005-06-15 | Graffinity Pharmaceuticals Aktiengesellschaft | Dpp-iv inhibitors |
| EP1541143A1 (en) | 2003-12-09 | 2005-06-15 | Graffinity Pharmaceuticals Aktiengesellschaft | Dpp-iv inhibitors |
| WO2005058849A1 (en) | 2003-12-15 | 2005-06-30 | Glenmark Pharmaceuticals Ltd. | New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them |
| US7550481B2 (en) | 2003-12-19 | 2009-06-23 | Merck & Co., Inc. | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease |
| EP1708707A1 (en) | 2004-01-22 | 2006-10-11 | Neurosearch A/S | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist |
| EP1715843A1 (en) | 2004-01-29 | 2006-11-02 | Neuromolecular Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions |
| WO2005075426A1 (en) | 2004-02-03 | 2005-08-18 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
| CA2554809C (en) * | 2004-02-05 | 2014-04-29 | Probiodrug Ag | Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase |
| WO2005079756A2 (en) | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
| US20050182044A1 (en) | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
| EP1758905B1 (de) | 2004-02-18 | 2009-04-29 | Boehringer Ingelheim International GmbH | 8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer |
| AU2005216970B2 (en) | 2004-02-23 | 2011-07-07 | Trustees Of Tufts College | Inhibitors of dipeptidylpeptidase IV for regulating glucose metabolism |
| EP1593671A1 (en) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV inhibitors |
| WO2005087235A1 (en) | 2004-03-09 | 2005-09-22 | National Health Research Institutes | Pyrrolidine compounds |
| UA85871C2 (uk) | 2004-03-15 | 2009-03-10 | Такеда Фармасьютікал Компані Лімітед | Інгібітори дипептидилпептидази |
| JP2007529556A (ja) | 2004-03-19 | 2007-10-25 | アクソニクス インコーポレイテッド | 認知障害の処置に有用なアセチルコリンエステラーゼ阻害剤およびｎ−メチル−ｄ−アスパラギン酸拮抗剤 |
| WO2005095339A1 (en) | 2004-03-31 | 2005-10-13 | Pfizer Products Inc. | Dicyanopyrrolidines as dipeptidyl peptidase iv inhibitors |
| WO2005097103A2 (en) | 2004-04-01 | 2005-10-20 | Axys Pharmaceuticals, Inc. | Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors |
| WO2005097768A2 (en) | 2004-04-05 | 2005-10-20 | Schering Corporation | Novel gamma secretase inhibitors |
| CA2563639A1 (en) | 2004-04-20 | 2005-11-03 | Merck & Co., Inc. | 2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| JP2007533743A (ja) | 2004-04-20 | 2007-11-22 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病治療のためのβ−セクレターゼ阻害薬として有用な１，３，５−置換フェニル誘導体化合物 |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| WO2005105133A2 (en) | 2004-04-23 | 2005-11-10 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
| JP2008504233A (ja) * | 2004-04-23 | 2008-02-14 | パラテック ファーマシューティカルズ インコーポレイテッド | 転写因子調節化合物およびその使用法 |
| WO2005108382A1 (en) | 2004-05-04 | 2005-11-17 | Merck & Co., Inc. | 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| PL1753748T3 (pl) | 2004-05-12 | 2010-01-29 | Pfizer Prod Inc | Pochodne proliny i ich zastosowanie jako inhibitorów peptydazy dipeptylowej IV |
| EP1756040A4 (en) | 2004-05-13 | 2008-04-30 | Merck & Co Inc | ALS-SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE, PHENYL ACETIC ACID AMID COMPOUNDS SUITABLE |
| WO2005116029A1 (en) | 2004-05-18 | 2005-12-08 | Merck & Co., Inc. | Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| EP1598341A1 (en) | 2004-05-21 | 2005-11-23 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
| US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| EP1604980A1 (en) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
| EP1604662A1 (en) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus |
| EP1604989A1 (en) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
| US7714021B2 (en) | 2004-06-15 | 2010-05-11 | Merck & Co., Inc. | Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease |
| GB0413389D0 (en) | 2004-06-16 | 2004-07-21 | Astrazeneca Ab | Chemical compounds |
| US7482336B2 (en) | 2004-06-21 | 2009-01-27 | Merck & Co., Inc. | Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| PE20060481A1 (es) | 2004-06-30 | 2006-06-19 | Schering Corp | N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas |
| CA2572289A1 (en) | 2004-06-30 | 2006-08-17 | Centocor, Inc. | Anti-mcp-1 antibodies, compositions, methods and uses |
| EP1778220A1 (en) | 2004-07-12 | 2007-05-02 | Phenomix Corporation | Constrained cyano compounds |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| CA2574218A1 (en) | 2004-07-22 | 2006-02-09 | Schering Corporation | Substituted amide beta secretase inhibitors |
| CA2575340A1 (en) | 2004-07-28 | 2006-02-09 | Schering Corporation | Macrocyclic beta-secretase inhibitors |
| HUP0401523A3 (en) | 2004-07-29 | 2007-05-02 | Richter Gedeon Vegyeszet | Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them |
| EP1623983A1 (en) | 2004-08-05 | 2006-02-08 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | Heterocyclic compounds useful as DPP-IV inhibitors |
| EP1784188B1 (en) | 2004-08-23 | 2010-07-14 | Merck Sharp & Dohme Corp. | Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| US20080058324A1 (en) | 2004-08-25 | 2008-03-06 | Santhera Pharmaceuticals (Schweiz) Ag | Alpha-Keto Carbonyl Calpain Inhibitors |
| AU2005276635A1 (en) | 2004-08-25 | 2006-03-02 | Santhera Pharmaceuticals (Schweiz) Ag | Alpha-keto carbonyl calpain inhibitors |
| US7388007B2 (en) | 2004-08-26 | 2008-06-17 | Bristol-Myers Squibb Company | Gamma-lactams as beta-secretase inhibitors |
| WO2006029850A1 (en) | 2004-09-14 | 2006-03-23 | The Genetics Company, Inc. | Hydrazone derivatives and their use as beta secretase inhibitors |
| AU2005286844A1 (en) | 2004-09-17 | 2006-03-30 | Comentis, Inc | Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof |
| EP1799660A2 (en) | 2004-09-17 | 2007-06-27 | Comentis, Inc. | Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof |
| JP4797021B2 (ja) | 2004-10-01 | 2011-10-19 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病の治療または予防用のジペプチジルペプチダ−ゼ−ｉｖ阻害剤としてのアミノピペリジン |
| WO2006042103A2 (en) | 2004-10-05 | 2006-04-20 | Axys Pharmaceuticals, Inc. | Reversible inhibitors of cathepsin b |
| CN101035536A (zh) | 2004-10-08 | 2007-09-12 | 诺瓦提斯公司 | 有机化合物的组合 |
| EP1807087A2 (en) | 2004-10-12 | 2007-07-18 | Ernir Snorrason | Inhibitors of acetylcholinesterase for treating skin diseases |
| US8114887B2 (en) | 2004-10-13 | 2012-02-14 | Merck, Sharp & Dohme Corp. | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| US20090004302A1 (en) | 2004-10-15 | 2009-01-01 | Biopharmacopae Design International Inc. | Methods and Therapeutic Compositions Comprising Plant Extracts for the Treatment of Cancer |
| AU2005299808B2 (en) | 2004-10-25 | 2009-08-20 | Novartis Ag | Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin |
| WO2006060109A1 (en) | 2004-10-29 | 2006-06-08 | Merck & Co., Inc. | 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| US7678783B2 (en) | 2004-11-17 | 2010-03-16 | Merck Sharp & Dohme Corp. | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease |
| CA2588295C (en) | 2004-11-23 | 2013-10-22 | Adamas Pharma, Llc | Method and composition for administering an nmda receptor antagonist to a subject |
| EP1817311B1 (en) | 2004-11-23 | 2012-10-17 | Merck Sharp & Dohme Corp. | 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| US7951949B2 (en) | 2004-11-23 | 2011-05-31 | Merck, Sharp & Dohme, Corp. | Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of Alzheimer's disease |
| EP2623099A1 (en) | 2004-11-24 | 2013-08-07 | Neuromolecular Pharmaceuticals, Inc | Composition and method for treating neurological disease |
| AU2005309606B2 (en) | 2004-11-29 | 2011-01-06 | Merck Sharp & Dohme Corp. | Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| RU2401267C2 (ru) | 2004-11-30 | 2010-10-10 | Ф.Хоффманн-Ля Рош Аг | Замещенные производные бензохинолизина |
| EP1827478A4 (en) | 2004-12-03 | 2009-08-05 | Mucosal Therapeutics Llc | METHODS OF TREATING JOINED OR SICK JOINTS |
| US7411093B2 (en) | 2004-12-20 | 2008-08-12 | Hoffman-La Roche Inc. | Aminocycloalkanes as DPP-IV inhibitors |
| EP1831165A1 (en) | 2004-12-20 | 2007-09-12 | F. Hoffmann-Roche AG | 4-aminopiperidine derivatives |
| JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| US20060142186A1 (en) | 2004-12-23 | 2006-06-29 | Voyager Pharmaceutical Corporation | Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of alzheimer's disease |
| WO2006070394A1 (en) | 2004-12-28 | 2006-07-06 | Council Of Scientific And Industrial Research | Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors |
| WO2006074265A2 (en) | 2005-01-06 | 2006-07-13 | Merck & Co., Inc. | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders |
| EP1855679B1 (en) | 2005-01-19 | 2016-06-29 | Merck Sharp & Dohme Corp. | Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease |
| US20060216331A1 (en) | 2005-02-28 | 2006-09-28 | Lines Thomas C | Composition for treating mental health disorders |
| WO2006094674A1 (en) | 2005-03-07 | 2006-09-14 | Michael Hermanussen | Nmda receptor antagonists in the medical intervention of metabolic disorders |
| US7745470B2 (en) | 2005-03-10 | 2010-06-29 | Bristol-Myers Squibb Company | Isophthalates as beta-secretase inhibitors |
| US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
| FR2883285B1 (fr) | 2005-03-17 | 2007-05-18 | Sanofi Aventis Sa | Sel besylate de la 7-(2-(4-(3-trifluoromethyl-phenyl) -1,2,3,6-tetrahudro-pyrid-1-yl)ethyl) isoquinoleine, sa preparation et son utilisation en therapeutique |
| US20080153791A1 (en) | 2005-03-18 | 2008-06-26 | Onpharm Gmbh | 11Beta -Hydroxysteroid Dehydrogenases |
| PE20061444A1 (es) | 2005-05-19 | 2007-01-15 | Centocor Inc | Anticuerpo anti-mcp-1, composiciones, metodos y usos |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| US20070203236A1 (en) * | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| GB0704100D0 (en) | 2006-03-17 | 2007-04-11 | Vodafone Plc | Improvements in an ehspa architecture |
| EA016584B1 (ru) * | 2006-09-21 | 2012-06-29 | Пробиодруг Аг | Новые гены, родственные гену глутаминилциклазы |
| WO2008127274A2 (en) * | 2006-09-22 | 2008-10-23 | Ptc Therapeutics, Inc. | Heterocyclic inhibitors of bacterial peptidyl trna hydrolase and uses thereof |
| ATE554085T1 (de) * | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| TW200843739A (en) * | 2007-03-30 | 2008-11-16 | Shionogi & Co | Novel pyrrolinone derivative and composition containing the same |
-
2007
- 2007-11-08 US US11/937,149 patent/US8278345B2/en not_active Expired - Fee Related
- 2007-11-08 EP EP07822336.9A patent/EP2089383B1/en active Active
- 2007-11-08 WO PCT/EP2007/062030 patent/WO2008055945A1/en not_active Ceased
- 2007-11-08 JP JP2009535728A patent/JP5379692B2/ja not_active Expired - Fee Related
-
2013
- 2013-07-25 JP JP2013154932A patent/JP5798157B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2089383B1 (en) | 2015-09-16 |
| JP5798157B2 (ja) | 2015-10-21 |
| US8278345B2 (en) | 2012-10-02 |
| US20090269301A1 (en) | 2009-10-29 |
| JP2013237688A (ja) | 2013-11-28 |
| JP2010509284A (ja) | 2010-03-25 |
| WO2008055945A1 (en) | 2008-05-15 |
| EP2089383A1 (en) | 2009-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5379692B2 (ja) | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 | |
| JP5599614B2 (ja) | グルタミニルシクラーゼの新規阻害剤 | |
| JP5523107B2 (ja) | グルタミニルシクラーゼの新規阻害剤 | |
| JP5456479B2 (ja) | グルタミニルシクラーゼの新規阻害剤 | |
| JP5675340B2 (ja) | 新規阻害剤 | |
| JP5612860B2 (ja) | グルタミニルシクラーゼ阻害剤としてのイミダゾ［１，５−ａ］ピリジン誘導体 | |
| JP5676249B2 (ja) | グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体 | |
| JP5667440B2 (ja) | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 | |
| JP5675343B2 (ja) | グルタミニルシクラーゼ阻害剤としての尿素誘導体 | |
| JP5675342B2 (ja) | グルタミニルシクラーゼ阻害剤としてのシアノグアニジン誘導体 | |
| JP5707327B2 (ja) | 新規の阻害剤 | |
| JP6026284B2 (ja) | グルタミニルシクラーゼの阻害剤 | |
| JP5675341B2 (ja) | グルタミニルシクラーゼ阻害剤としてのチオキソキナゾリノン誘導体 | |
| JP5675344B2 (ja) | グルタミニルシクラーゼ阻害剤としてのニトロビニルジアミン誘導体 | |
| JP5688745B2 (ja) | グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤 | |
| US8420684B2 (en) | Inhibitors of glutaminyl cyclase | |
| JP6050264B2 (ja) | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 | |
| HK1161540A (en) | Novel inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130129 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130422 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130430 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130725 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130903 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130927 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5379692 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |